Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY)
:DRREDDY
Earnings Data
Report Date
May 08, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
11.82Last Year’s EPS
19.11Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The quarter shows resilience in core branded businesses (India, emerging markets, NRT) with meaningful product-launch and pipeline progress, healthy cash position and strategic collaborations. However, earnings and margins were pressured by lower Lenalidomide revenue, pricing erosion in unbranded generics, elevated SG&A and one-time labor provisions, and regulatory uncertainties for key biologics in the U.S. The business is executing on strategic priorities and long-term growth drivers, but near-term financial headwinds and regulatory timing create caution.Company Guidance
Consolidated Revenue Growth
Consolidated revenue of INR 8,727 crore (USD 971m) in Q3 FY'26, up 4.4% YoY (down 0.9% QoQ); underlying base business (ex-Lenalidomide) delivered double-digit growth aided by favorable forex.
Strong India and Emerging Markets Performance
India revenue INR 1,603 crore, up 19% YoY (2% QoQ); organic India growth ~17%–18% excluding recent Stugeron acquisition. Emerging markets revenue INR 1,896 crore, up 32% YoY and 15% QoQ; Russia grew ~21% YoY and 16% QoQ in constant currency.
Adjusted Profitability Metrics
Reported EBITDA INR 2,049 crore (USD 228m); reported EBITDA margin 23.5% (down YoY), adjusted EBITDA margin 24.8% excluding one-time labor-code provision (company cites ~25% underlying EBITDA margin).
Pipeline and Regulatory Progress — Semaglutide & Abatacept
Received semaglutide marketing authorization in India, COPP filings underway in emerging markets and Health Canada response submitted (goal date by May). BLA for IV abatacept filed in Dec 2025 on schedule; subcutaneous abatacept US filing planned July 2026.
Business Development Wins
Strategic collaboration with Immutep for Eftilagimod Alfa (USD 20m upfront, up to USD 350m in milestones + royalties); launched Hevaxin (Hepatitis-E vaccine) in India; continued integration of acquired NRT business (85% by value under operational control).
Product Launches and Filings Momentum
Launched multiple products: 6 new products in North America, 10 new generics across markets, 30 new products across emerging markets, 2 new brands in India. Filed 31 DMFs globally and completed 28 global generic filings in the quarter.
Regulatory Inspection Outcomes and CDMO Wins
USFDA inspection at API facility CTO-SEZ returned 0 observations; Aurigene (CDMO) was exclusive API manufacturer for 2 novel USFDA-approved drugs in 2025 and delivered AI-assisted discovery programs, supporting future CDMO revenue growth.
Strong Balance Sheet and Cash Generation
Net cash surplus of INR 3,069 crore (USD 342m) as of Dec 31, 2025. CapEx in Q3 INR 669 crore (USD 75m) and free cash flow INR 374 crore (USD 42m). Currency hedges in place (USD ~481m through Mar 2027).
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) Earnings, Revenues Date & History
IN:DRREDDY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IN:DRREDDY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 21, 2026 | ₹1166.90 | ₹1155.50 | -0.98% |
Oct 24, 2025 | ₹1279.85 | ₹1284.00 | +0.32% |
Jul 23, 2025 | ₹1240.40 | ₹1247.55 | +0.58% |
May 09, 2025 | ₹1141.46 | ₹1149.11 | +0.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) report earnings?
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) is schdueled to report earning on May 08, 2026, Before Open (Confirmed).
What is Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time?
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time is at May 08, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Dr. Reddy's Laboratories Ltd. stock?
The P/E ratio of Dr. Reddy's Laboratories Ltd. is N/A.
What is IN:DRREDDY EPS forecast?
IN:DRREDDY EPS forecast for the fiscal quarter 2026 (Q4) is 11.82.